The Effect of 6 Months’ Treatment With Pasireotide LAR on Glucose Metabolism in Patients With Resistant Acromegaly in Real-World Clinical Settings
ObjectiveThe aim of the study was to evaluate glucose metabolism, as measured by glycated hemoglobin (HbA1c) levels and the need for antidiabetic medical treatment, in patients with acromegaly resistant to first-generation somatostatin receptors ligands (SRLs) treated with pasireotide long-acting re...
Main Authors: | Przemysław Witek, Marek Bolanowski, Katarzyna Szamotulska, Agnieszka Wojciechowska-Luźniak, Aleksandra Jawiarczyk-Przybyłowska, Marcin Kałużny |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2021-03-01
|
Series: | Frontiers in Endocrinology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fendo.2021.633944/full |
Similar Items
-
Risk factors and management of pasireotide-associated hyperglycemia in acromegaly
by: Mônica R Gadelha, et al.
Published: (2020-12-01) -
Pasireotide-LAR in acromegaly patients treated with a combination therapy: a real-life study
by: Hélène Lasolle, et al.
Published: (2019-10-01) -
Pasireotide: A new option for treatment of acromegaly
by: Filiz Eksi Haydardedeoglu, et al.
Published: (2020-06-01) -
Successful Control of Hypoglycemia with Pasireotide LAR in a Patient with Inappropriate Insulin Secretion
by: Rouland A, et al.
Published: (2021-02-01) -
New cross-roads for second line medical therapy in acromegaly
by: Adina Ghemigian, et al.
Published: (2018-03-01)